Coverage
Filings
Novo Nordisk said Wednesday it plans to cut approximately 9,000 jobs globally as part of a major restructuring aimed at refocusing on its core diabetes and obesity drug businesses amid slowing growth.
Novo Nordisk said Friday its popular weight-loss drug Wegovy has been approved by the U.S. Food and Drug Administration to treat a common type of liver disease, further expanding the blockbuster drug's market.
Novo Nordisk said Thursday it will advance both injectable and oral versions of its experimental obesity drug, amycretin, into late-stage Phase 3 clinical trials.
| Novo Nordisk A/S - Share repurchase programme | 15 Oct 2018 |
| Novo Nordisk A/S - Share repurchase programme | 8 Oct 2018 |
| Novo Nordisk A/S - Share repurchase programme | 1 Oct 2018 |
| Novo Nordisk A/S - Share repurchase programme | 24 Sept 2018 |
| Novo Nordisk - Oral semaglutide demonstrates greater reductions in HbA1c and body weight and comparable number of adverse events vs dulaglutide in Japanese people with type 2 diabetes | 20 Sept 2018 |